Hydroxychloroquine exacerbates imiquimod-induced psoriasis-like dermatitis through stimulating overexpression of IL-6 in keratinocytes

References

• Takahashi T, Yamasaki K. Psoriasis and antimicrobial peptides. Int J Mol Sci. 2020;21(18):6791. doi:10.3390/ijms21186791.
   PubMed Web of Science ®Google Scholar
• Tian D, Lai Y. The relapse of psoriasis: mechanisms and mysteries. JID Innov. 2022;2(3):100116. doi:10.1016/j.xjidi.2022.100116.
   PubMedGoogle Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7(12):718–729. doi:10.1038/nrneph.2011.150.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Gudsoorkar VS, Weisman MH, et al. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8(9):522–533. doi:10.1038/nrrheum.2012.106.
   PubMed Web of Science ®Google Scholar
• Chandler LC, Yusuf IH, McClements ME, et al. Immunomodulatory effects of hydroxychloroquine and chloroquine in viral infections and their potential application in retinal gene therapy. Int J Mol Sci. 2020;21(14):4972. doi:10.3390/ijms21144972.
   PubMed Web of Science ®Google Scholar
• Nirk EL, Reggiori F, Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med. 2020;12(8):e12476. doi:10.15252/emmm.202012476.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–166. doi:10.1038/s41584-020-0372-x.
   PubMed Web of Science ®Google Scholar
• Yang J, Yang X, Yang J, et al. Hydroxychloroquine inhibits the differentiation of Th17 cells in systemic lupus erythematosus. J Rheumatol. 2018;45(6):818–826. doi:10.3899/jrheum.170737.
   PubMed Web of Science ®Google Scholar
• Shah K, Lee WW, Lee SH, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(2):R53. doi:10.1186/ar2964.
   PubMed Web of Science ®Google Scholar
• Talaat RM, Mohamed SF, Bassyouni IH, et al. Th1/Th2/Th17/treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine. 2015;72(2):146–153. doi:10.1016/j.cyto.2014.12.027.
   PubMed Web of Science ®Google Scholar
• Degos R, Touraine R, Civatte J, et al. Erythroderma with appearance of pustular psoriasis during a case of duhring’s disease treated with hydroxychloroquine. Bull Soc Fr Dermatol Syphiligr. 1963;70:129–134.
   PubMedGoogle Scholar
• Gray RG. Hydroxychloroquine provocation of psoriasis. J Rheumatol. 1985;12(2):391.
   PubMed Web of Science ®Google Scholar
• Friedman SJ. Pustular psoriasis associated with hydroxychloroquine. J Am Acad Dermatol. 1987;16(6):1256–1257. doi:10.1016/s0190-9622(87)80021-x.
   PubMed Web of Science ®Google Scholar
• Vestey JP, Savin JA. Psoriasis worsened by antimalarial prophylaxis. J Infect. 1992;24(2):211–212. doi:10.1016/0163-4453(92)93058-x.
   PubMed Web of Science ®Google Scholar
• Astudillo L, Sailler L, Carreiro M[, et al. Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems. Ann Med Interne (Paris). 2003;154(1):3–6.
   PubMedGoogle Scholar
• Welsch MJ. Acute pustular psoriasis complicated by leukocytoclastic vasculitis. J Drugs Dermatol. 2003;2(2):193–197.
   PubMedGoogle Scholar
• Ullah A, Zeb H, Khakwani Z, et al. Hydroxychloroquine-induced inverse psoriasis. BMJ Case Rep. 2019;12(2):bcr-2018-224619. doi:10.1136/bcr-2018-224619.
   Google Scholar
• Midorikawa H, Kiniwa Y, Minagawa A, et al. Case of annular pustular psoriasis/circinate erythematous psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus: possible association with CARD-14 mutation. J Dermatol. 2021;48(9):e440–e442. doi:10.1111/1346-8138.15976.
   PubMed Web of Science ®Google Scholar
• Öncü INS, Güler D, Gürel G. Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19. Dermatol Ther. 2021;34(2):e14806. doi:10.1111/dth.14806.
   PubMed Web of Science ®Google Scholar
• Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol. 1999;455:221–225. doi:10.1007/978-1-4615-4857-7_32.
   PubMed Web of Science ®Google Scholar
• Marin S, Martin Val A, Bosch Peligero M, et al. Safety of short-term treatments with oral chloroquine and hydroxychloroquine in patients with and without COVID-19: a systematic review. Pharmaceuticals (Basel). 2022;15(5). doi:10.3390/ph15050634.
   PubMedGoogle Scholar
• Sachdeva M, Mufti A, Maliyar K, et al. Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment. J Am Acad Dermatol. 2020;83(2):579–586. doi:10.1016/j.jaad.2020.05.074.
   PubMed Web of Science ®Google Scholar
• Wolf R, Schiavo AL, Lombardi ML, et al. The in vitro effect of hydroxychloroquine on skin morphology in psoriasis. Int J Dermatol. 1999;38(2):154–157. doi:10.1046/j.1365-4362.1999.00574.x.
   PubMed Web of Science ®Google Scholar
• Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature’s biological glues. Biochem J. 2002;368(Pt 2):377–396. doi:10.1042/BJ20021234.
   PubMed Web of Science ®Google Scholar
• Wolf R, Lo Schiavo A, Lombardi ML, et al. The in vitro effect of hydroxychloroquine on skin morphology and transglutaminase. Int J Dermatol. 1997;36(9):704–707. doi:10.1046/j.1365-4362.1997.00227.x.
   PubMed Web of Science ®Google Scholar
• Said A, Bock S, Lajqi T, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived langerhans-like cells. J Immunol (Baltimore, Md: 1950). 2014;193(12):6135–6143. doi:10.4049/jimmunol.1303276.
   PubMed Web of Science ®Google Scholar
• Yen LJ, Yen CY, Li CL, et al. Brevilin a ameliorates imiquimod-induced psoriasis-like dermatitis and reduces Th17 differentiation in psoriasis patients. J Pers Med. 2022;12(11):1888. doi:10.3390/jpm12111888.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Follansbee T, Wu X, et al. TRPV1 mediates inflammation and hyperplasia in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) in mice. J Dermatol Sci. 2018;92(3):264–271. doi:10.1016/j.jdermsci.2018.11.009.
   PubMed Web of Science ®Google Scholar
• Percie Du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Br J Pharmacol. 2020;177(16):3617–3624. doi:10.1111/bph.15193.
   PubMed Web of Science ®Google Scholar
• Lin H, Li CL, Yen LJ, et al. Forsythoside a alleviates Imiquimod-Induced psoriasis-like dermatitis in mice by regulating Th17 cells and IL-17A expression. J Pers Med. 2022;12(1). doi:10.3390/jpm12010062.
   Web of Science ®Google Scholar
• Yoon YH, Cho KS, Hwang JJ, et al. Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest Ophthalmol Vis Sci. 2010;51(11):6030–6037. doi:10.1167/iovs.10-5278.
   PubMed Web of Science ®Google Scholar
• van den Borne BE, Dijkmans BA, de Rooij HH, et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24(1):55–60.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Dunogué B, Morel N, et al. Hydroxy­chloroquine: a multifaceted treatment in lupus. Presse Med. 2014;43(6 Pt 2):e167-80–e180. doi:10.1016/j.lpm.2014.03.007.
   PubMed Web of Science ®Google Scholar
• Li B, Huang L, Lv P, et al. The role of Th17 cells in psoriasis. Immunol Res. 2020;68(5):296–309. doi:10.1007/s12026-020-09149-1.
   PubMed Web of Science ®Google Scholar
• Benhadou F, Mintoff D, Del Marmol V. Psoriasis: keratinocytes or immune cells - which is the trigger? Dermatology. 2019;235(2):91–100. doi:10.1159/000495291.
   PubMed Web of Science ®Google Scholar
• Pfaff CM, Marquardt Y, Fietkau K, et al. The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. Sci Rep. 2017;7(1):15631. doi:10.1038/s41598-017-15892-7.
   PubMedGoogle Scholar
• Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–1835. doi:10.1002/eji.201040391.
   PubMed Web of Science ®Google Scholar
• van den Bogaard EH, Tjabringa GS, Joosten I, et al. Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases. J Invest Dermatol. 2014;134(3):719–727. doi:10.1038/jid.2013.417.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967–974. doi:10.1038/ni1488.
   PubMed Web of Science ®Google Scholar
• Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6(3):315–325. doi:10.1016/s1074-7613(00)80334-9.
   PubMed Web of Science ®Google Scholar
• Roy M, Richard JF, Dumas A, et al. CXCL1 can be regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during bacterial toxin exposure and encephalomyelitis. J Neuro­inflammation. 2012;9(1):18. doi:10.1186/1742-2094-9-18.
   PubMedGoogle Scholar
• Dawicki W, Jawdat DW, Xu N, et al. Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J Immunol. 2010;184(4):2116–2123. doi:10.4049/jimmunol.0803894.
   PubMed Web of Science ®Google Scholar
• Bernardo D, Vallejo-Díez S, Mann ER, et al. IL-6 promotes immune responses in human ulcerative colitis and induces a skin-homing phenotype in the dendritic cells and T cells they stimulate. Eur J Immunol. 2012;42(5):1337–1353. doi:10.1002/eji.201142327.
   PubMed Web of Science ®Google Scholar
• Xu Y-D, Cheng M, Shang P-P, et al. Role of IL-6 in dendritic cell functions. J Leukoc Biol. 2022;111(3):695–709. doi:10.1002/JLB.3MR0621-616RR.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Gisondi P, Carrascosa JM, et al. The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(8):1695–1706. doi:10.1111/jdv.16273.
   PubMed Web of Science ®Google Scholar
• Hitomi K. Transglutaminases in skin epidermis. Eur J Dermatol. 2005;15(5):313–319.
   PubMed Web of Science ®Google Scholar
• Eckert RL, Sturniolo MT, Broome AM, et al. Transglutaminase function in epidermis. J Investig Dermatol. 2005;124(3):481–492. doi:10.1111/j.0022-202X.2005.23627.x.
   PubMed Web of Science ®Google Scholar
• Orsmond A, Bereza-Malcolm L, Lynch T, et al. Skin barrier dysregulation in psoriasis. IJMS. 2021;22(19):10841. doi:10.3390/ijms221910841.
   Google Scholar